A carregar...
Clinical Characteristics and Risk of Relapse for Patients with Stage I–II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy
Diffuse large b-cell lymphoma (DLBCL) is an aggressive and potentially curable lymphoma that presents itself as stage I–II in 30% of all cases. It is known that in these localized stages, 15–20% of patients treated without rituximab eventually relapse, but less data exist regarding rituximab era. We...
Na minha lista:
| Publicado no: | Clin Med Insights Blood Disord |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Libertas Academica
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4222304/ https://ncbi.nlm.nih.gov/pubmed/25512717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMBD.S12713 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|